Both Marker Therapeutics Inc. (NASDAQ:MRKR) and Unum Therapeutics Inc. (NASDAQ:UMRX) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics Inc.	N/A	1481.05	147.96M	-1.28	0.00
Unum Therapeutics Inc.	9.73M	13.60	34.55M	-1.54	0.00

Table 1 demonstrates Marker Therapeutics Inc. and Unum Therapeutics Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us Marker Therapeutics Inc. and Unum Therapeutics Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics Inc.	0.00%	-662.2%	-295.8%
Unum Therapeutics Inc.	-355.09%	-383.1%	-45%

Liquidity

The current Quick Ratio of Marker Therapeutics Inc. is 1.2 while its Current Ratio is 1.2. Meanwhile, Unum Therapeutics Inc. has a Current Ratio of 3.4 while its Quick Ratio is 3.4. Unum Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Marker Therapeutics Inc.

Institutional and Insider Ownership

The shares of both Marker Therapeutics Inc. and Unum Therapeutics Inc. are owned by institutional investors at 43.5% and 47.9% respectively. 22.8% are Marker Therapeutics Inc.’s share held by insiders. Comparatively, 39.89% are Unum Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Marker Therapeutics Inc.	-3.11%	17.96%	-10.86%	-12.11%	96.23%	12.43%
Unum Therapeutics Inc.	3.26%	2.55%	-30.78%	-72.28%	0%	0.68%

For the past year Marker Therapeutics Inc. was more bullish than Unum Therapeutics Inc.

Summary

Unum Therapeutics Inc. beats on 5 of the 9 factors Marker Therapeutics Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.